Xencor Inc. Files 8-K for Regulation FD Disclosure
Ticker: XNCR · Form: 8-K · Filed: Mar 6, 2024 · CIK: 1326732
| Field | Detail |
|---|---|
| Company | Xencor Inc (XNCR) |
| Form Type | 8-K |
| Filed Date | Mar 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulation-fd
Related Tickers: XNCR
TL;DR
Xencor filed an 8-K, standard disclosure. Nothing major revealed yet.
AI Summary
On March 6, 2024, Xencor Inc. filed an 8-K report. The filing indicates that the company is providing a Regulation FD Disclosure. No specific financial transactions or material events were detailed in the provided excerpt, but the filing itself is a standard disclosure requirement.
Why It Matters
This filing serves as a public announcement to ensure all investors receive material information simultaneously, as required by Regulation FD.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not appear to contain any new material negative information.
Key Numbers
- 001-36182 — SEC File Number (Identifies the company's filings with the SEC.)
- 20-1622502 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Xencor Inc. (company) — Registrant
- March 6, 2024 (date) — Date of earliest event reported
- Regulation FD (regulation) — Type of disclosure
- Delaware (jurisdiction) — State of incorporation
- Pasadena, California (location) — Principal executive offices
FAQ
What specific information is being disclosed under Regulation FD?
The provided excerpt does not detail the specific information being disclosed under Regulation FD, only that the filing is for this purpose.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on March 6, 2024.
What is Xencor Inc.'s principal executive office address?
Xencor Inc.'s principal executive office is located at 465 North Halstead Street, Suite 200, Pasadena, California 91107.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the SEC file number for Xencor Inc.?
The SEC file number for Xencor Inc. is 001-36182.
Filing Stats: 565 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-03-06 08:32:26
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share XNCR Nasdaq Global Market I
Filing Documents
- xncr-20240306.htm (8-K) — 25KB
- xencor_corporatexpresent.htm (EX-99) — 39KB
- xencor_corporatexpresent001.jpg (GRAPHIC) — 43KB
- xencor_corporatexpresent002.jpg (GRAPHIC) — 223KB
- xencor_corporatexpresent003.jpg (GRAPHIC) — 129KB
- xencor_corporatexpresent004.jpg (GRAPHIC) — 126KB
- xencor_corporatexpresent005.jpg (GRAPHIC) — 120KB
- xencor_corporatexpresent006.jpg (GRAPHIC) — 95KB
- xencor_corporatexpresent007.jpg (GRAPHIC) — 120KB
- xencor_corporatexpresent008.jpg (GRAPHIC) — 136KB
- xencor_corporatexpresent009.jpg (GRAPHIC) — 47KB
- xencor_corporatexpresent010.jpg (GRAPHIC) — 96KB
- xencor_corporatexpresent011.jpg (GRAPHIC) — 51KB
- xencor_corporatexpresent012.jpg (GRAPHIC) — 121KB
- xencor_corporatexpresent013.jpg (GRAPHIC) — 136KB
- xencor_corporatexpresent014.jpg (GRAPHIC) — 117KB
- xencor_corporatexpresent015.jpg (GRAPHIC) — 164KB
- xencor_corporatexpresent016.jpg (GRAPHIC) — 143KB
- xencor_corporatexpresent017.jpg (GRAPHIC) — 147KB
- xencor_corporatexpresent018.jpg (GRAPHIC) — 41KB
- xencor_corporatexpresent019.jpg (GRAPHIC) — 108KB
- xencor_corporatexpresent020.jpg (GRAPHIC) — 107KB
- xencor_corporatexpresent021.jpg (GRAPHIC) — 107KB
- xencor_corporatexpresent022.jpg (GRAPHIC) — 148KB
- xencor_corporatexpresent023.jpg (GRAPHIC) — 121KB
- xencor_corporatexpresent024.jpg (GRAPHIC) — 43KB
- xencor_corporatexpresent025.jpg (GRAPHIC) — 45KB
- xencor_corporatexpresent026.jpg (GRAPHIC) — 106KB
- xencor_corporatexpresent027.jpg (GRAPHIC) — 104KB
- xencor_corporatexpresent028.jpg (GRAPHIC) — 109KB
- xencor_corporatexpresent029.jpg (GRAPHIC) — 105KB
- xencor_corporatexpresent030.jpg (GRAPHIC) — 70KB
- xencor_corporatexpresent031.jpg (GRAPHIC) — 120KB
- xencor_corporatexpresent032.jpg (GRAPHIC) — 86KB
- xencor_corporatexpresent033.jpg (GRAPHIC) — 91KB
- xencor_corporatexpresent034.jpg (GRAPHIC) — 104KB
- xencor_corporatexpresent035.jpg (GRAPHIC) — 118KB
- xencor_corporatexpresent036.jpg (GRAPHIC) — 171KB
- xencor_corporatexpresent037.jpg (GRAPHIC) — 116KB
- xencor_corporatexpresent038.jpg (GRAPHIC) — 45KB
- 0001326732-24-000009.txt ( ) — 5826KB
- xncr-20240306.xsd (EX-101.SCH) — 2KB
- xncr-20240306_lab.xml (EX-101.LAB) — 21KB
- xncr-20240306_pre.xml (EX-101.PRE) — 12KB
- xncr-20240306_htm.xml (XML) — 3KB
01 Regulation FD
Item 7.01 Regulation FD On March 6, 2024, the Company posted a presentation on the "Investors" section of the Company's website (www.xencor.com), which includes additional clinical data from the Phase 2 study of vudalimab (PD1 x CTLA-4) monotherapy in patients with metastatic castration resistant prostate cancer. The information contained in, or that can be accessed through, the Company's website is not a part of this filing. A copy of the presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in "Item 7.01" and in Exhibit 99.1 attached hereto is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, Except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Pre s entation dated March 6, 2024 . 104 Cover Page Interactive Data File (formatted as inline XBRL). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 6, 2024 XENCOR, INC. By: /s/ Celia Eckert Celia Eckert General Counsel & Corporate Secretary 3